Risk factors

The Touchstone acquisition integration risk was dropped as the October 2024 merger concluded.

Genesco highlights new risks around a multi-year IT restructuring initiative extending through Fiscal 2027 and third-party AI processing.

5G commercialization is advancing, but growth depends on carrier adoption, customer demand, and scaling initial chipset shipments.

The filing indicates no added, dropped, or reworded risk factors for Health In Tech, Inc. this year.

Cash and cash equivalents grew to $100.4 million as of December 31, 2025, up from $17.7 million.

Severe going concern doubt, low cash of $3.6 million, and dropping public float to $20.1 million threaten survival. Net loss widened to $9.1 million and accumulated deficit reached $127.1 million in 2025. TraceCop cybersecurity solution generates 43.2% of revenues, highlighting customer concentration.

TOI’s control over KIO-301 development and commercialization is a central risk, including possible discontinuation or narrower indications.

Lucid Diagnostics relies heavily on commercializing its EsoGuard test and EsoCheck device, facing going concern doubts and the need for capital.

Losses deepened as accumulated deficit grew to $32.3 million in 2025.

Maze Therapeutics added significant debt obligations through a new $200.0 million credit facility with Hercules Capital. The company highlighted increased financing activities, including private placements of common stock and pre-funded warrants.

The company relies heavily on government contracts like BARDA and DOD for funding its DeepView diagnostic systems. Regulatory approval from the FDA and international bodies remains a central milestone for commercialization. Proprietary AI algorithms and extensive wound data repositories form the core of the business model.

Going concern doubt hangs over operations due to ongoing operating losses and a limited operating history. Reliance on the University of Pittsburgh license is absolute for the core SkinJect asset. Integration of recently acquired Antev and its Teverelix asset presents execution risk.